Page 20 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

A B

C D E

F

Figure 10. Coordination environments of natural Mn-SOD (A) and catalase (B). (C) Chemical structure of the biomimetic nanocatalyst. (D) Zn(COO) 4
metal node and MnTCPP in the nanocatalyst. (E) Layered structure of the nanocatalyst. (F) Antiarthritic mechanism of the biomimetic nanocatalyst.
+
Reproduced with permission from Yang et al. Copyright © 2022, Nature Publishing Group.
166
stress is a key pathogenic factor of osteoporosis, which by osteoblasts, leading to osteoporosis. Current anti-
191
initiates the overactivation of osteoclasts to secrete a large osteoporosis drugs, such as Vitamin D, alendronate sodium,
192
amount of acidic substance (lactic acid and citric acid) and and zoledronic acid, cannot scavenge ROS efficiently, and
form an acidic microenvironment subsequently (pH ≈ 4.5), they only present insufficient therapeutic efficacy. 193
degrading bone into Ca . If osteoblasts cannot A recent study reported that Prussian blue nanoparticles
2+ 189,190
mineralize these Ca efficiently into bone tissue, the bone can be used for delaying osteoporosis. This nanocatalyst
2+
194
resorption by osteoclasts will exceed bone regeneration can trigger catalytic ROS-scavenging reactions to normalize
Volume 1 Issue 1 (2024) 14 doi: 10.36922/imo.2527